Canadian Cancer Trials Group Bulletins

Group Administrators Office


Canadian Cancer Trials Group and ASCO 2014

A number of abstracts related to Canadian Cancer Trials Group trials or trials which included Canadian Cancer Trials Group participation are being presented at the American Society of Clinical Oncology Annual Meeting in Chicago, May 30 - June 3, 2014, including three that have been selected as oral presentations.

Canadian Cancer Trials Group MA.21
Prognostic associations of 25OH vitamin D in Canadian Cancer Trials Group MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC) (Abstract #504)
Authors: Ana Elisa Lohmann, Judy-Anne W. Chapman, Margot J. Burnell, Mark Norman Levine, Elena Tsvetkova, Kathleen I. Pritchard, Karen A. Gelmon, Patti O'Brien, Lei Han, Hope S. Rugo, Kathy S. Albain, Edith A. Perez, Theodore A. Vandenberg, Haji I. Chalchal, Ravinder Pal Singh Sawhney, Lois E. Shepherd, Pamela Jean Goodwin

http://abstracts.asco.org/144/AbstView_144_128900.html
________________________________________________________

Canadian Cancer Trials Group MAC.4 (IBCSG SOFT)/ Canadian Cancer Trials Group MAC.5 (IBCSG TEXT)
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials (Abstract #LBA1)
Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, Istvan Lang, Henry Leonidas Gomez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Herve R. Bonnefoi, Silvana Martino, Charles E. Geyer, Manuela Rabaglio-Poretti, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis

http://abstracts.asco.org/144/AbstView_144_129398.html

________________________________________________________

Canadian Cancer Trials Group MAC.13 (BIG 2-06; NCCTG [Alliance] N063D)
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) (Abstract #LBA4)
Authors: Martine J. Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro De Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E. Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D. Gelber, Edith A. Perez

http://abstracts.asco.org/144/AbstView_144_128258.html


For a complete listing of abstracts being presented, please use this link ... http://www.ctg.queensu.ca/public/publications/publications.html